Tributary Capital Management LLC Acquires 244,483 Shares of Integra LifeSciences Holdings Corporation (IART)

Tributary Capital Management LLC boosted its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 148.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 408,960 shares of the life sciences company’s stock after buying an additional 244,483 shares during the period. Integra LifeSciences Holdings Corporation makes up 1.7% of Tributary Capital Management LLC’s portfolio, making the stock its 12th largest position. Tributary Capital Management LLC owned about 0.54% of Integra LifeSciences Holdings Corporation worth $17,229,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Integra LifeSciences Holdings Corporation by 77.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,697 shares of the life sciences company’s stock worth $100,000 after buying an additional 742 shares during the period. LS Investment Advisors LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 90.7% in the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock worth $102,000 after buying an additional 1,147 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Integra LifeSciences Holdings Corporation by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock worth $107,000 after buying an additional 1,751 shares during the period. First Manhattan Co. purchased a new position in shares of Integra LifeSciences Holdings Corporation during the first quarter worth $117,000. Finally, Elkfork Partners LLC purchased a new position in shares of Integra LifeSciences Holdings Corporation during the fourth quarter worth $125,000. Institutional investors and hedge funds own 89.74% of the company’s stock.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.13% during mid-day trading on Friday, hitting $52.79. 924,301 shares of the stock traded hands. The firm’s 50-day moving average is $48.87 and its 200-day moving average is $51.04. Integra LifeSciences Holdings Corporation has a 12-month low of $37.38 and a 12-month high of $53.07. The company has a market cap of $3.99 billion, a price-to-earnings ratio of 62.85 and a beta of 0.76.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by $0.01. The firm had revenue of $258.60 million for the quarter, compared to analysts’ expectations of $254.19 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.67% and a net margin of 6.66%. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 earnings per share. Equities research analysts expect that Integra LifeSciences Holdings Corporation will post $1.92 EPS for the current year.

WARNING: “Tributary Capital Management LLC Acquires 244,483 Shares of Integra LifeSciences Holdings Corporation (IART)” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/06/16/tributary-capital-management-llc-has-17-229-million-stake-in-integra-lifesciences-holdings-corp-iart-updated-updated.html.

IART has been the subject of a number of research reports. Piper Jaffray Companies reissued an “overweight” rating and set a $47.00 target price on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, March 22nd. ValuEngine cut shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Jefferies Group LLC upped their price objective on shares of Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Monday, May 15th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, May 2nd. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $49.50.

In related news, VP Glenn Coleman sold 13,865 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The shares were sold at an average price of $45.91, for a total value of $636,542.15. Following the completion of the sale, the vice president now directly owns 18,519 shares in the company, valued at $850,207.29. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stuart Essig sold 135,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the completion of the sale, the director now owns 2,077,475 shares of the company’s stock, valued at $103,666,002.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 304,523 shares of company stock valued at $14,812,988. Insiders own 21.40% of the company’s stock.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply